Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3974 SAD and MAD in Healthy Participants
NCT07290283Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD3974, sponsored by AstraZeneca. Primary endpoint: Number of participants with adverse events (AEs) and serious adverse events (SAEs). Started Dec 2025; status: recruiting.
02
Drugs
AZD3974
Beyond the preview
Go deeper on NCT07290283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290283.